An observational study in SARS-CoV-2 Pneumonia, sponsored by University of Bologna. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-04-07.
Sponsored by University of Bologna · Observational
The emergence of SARS-CoV-2 is currently engaging and consuming most of resources of efficient healthcare systems in Europe, and several hospitals are currently experiencing a shortage of ICU beds for critically-ill patients with SARS-CoV-2 pneumonia.
A risk stratification based on clinical, radiological and laboratory parameters seems necessary in order to better identify those patients who may need ICU admission and/or those who may benefit from a prompt antiviral therapy
The study will compared patients with and without respiratory failure in order to find risk factors for need for ICU admission. A simple score based on risk factors will be created from a multicenter Italian cohort and validated in a multicenter international cohort.
University of Bologna is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The population of the study will include all consecutive hospitalized patients with microbiologically confirmed diagnosis of SARS-CoV-2 infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020. .
Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
Respiratory failure
Composite of ICU admission or SpO2\<92% with 100% FiO2 of oxygen treatment (reservoir mask or CPAP or NIV), respiratory rate \>30 bpm, respiratory distress
Time frame: 14 days
Occurence of bacterial superinfection
Incidence of bacterial superinfection among ventilated patients with SARS-CoV-2 pneumonia
Time frame: 14 days
Plan to share: Undecided — Participant from other centers may request to analyze the registry for other purposes upon IRB and study group approval
Started Mar 2020 (actual). Primary completion is estimated for Apr 2020, 1 month after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.